ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / December 3, 2019 / Molecular Partners AG (SIX:MOLN)
We’re looking forward to welcoming you at Molecular Partners’ R&D Day on Thursday, December 12, 2019 from 7:30am to 10:00am.
The event will take place at The Yale Club, 50 Vanderbilt Avenue, New York City. Click here for directions.
Below is a detailed agenda of the event.
If you have any questions about the event or in order to register, please contact Susan A. Noonan at firstname.lastname@example.org.
Agenda R&D Day 2019 – Novel Therapeutic Designs Applied
7:30am: Registration & Breakfast
8:00-8:20: Corporate Overview
Dr. Patrick Amstutz
Chief Executive Officer, Molecular Partners
8:20-8:35: Abicipar – Presentation of Recently Updated 2 Year Data
Dr. Jeremy Wolfe
Practicing Ophthalmology Specialist
8:35-8:50: MP0250 Trial in Multiple Myeloma
Dr. Stefan Knop
Department Head Hematology, University of Würzburg, Germany
8:50-9:00: Clinical Pipeline
Dr. Nicolas Leupin
Chief Medical Officer, Molecular Partners
9:00-9:15: Preclinical Pipeline
Dr. Daniel Steiner
SVP Research, Molecular Partners
9:15-9:30: Novel Therapeutic Designs
Dr. Jordi Rodon Ahnert
Associate Professor, Department of Investigational Cancer Therapeutics
MD Anderson Cancer Center
9:30-9:35: Summary & Key Takeaways
About Molecular Partners AG
Molecular Partners AG is a clinical-stage biotech company that is developing a new class of therapies known as DARPin® therapeutics. The company continues to attract talented individuals who share the passion to develop breakthrough medicines for serious diseases. Molecular Partners has compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on oncology and immuno-oncology. The company establishes research and development partnerships with leading pharmaceutical companies and is backed by established biotech investors.
For more information regarding Molecular Partners AG, go to: www.molecularpartners.com.
Molecular Partners AG
Phone: +41 44 755 77 00
SOURCE: Molecular Partners AG
View source version on accesswire.com: